Discounted Cash Flow (DCF) Analysis Unlevered

Madrigal Pharmaceuticals, Inc. (MDGL)

$236.54

-11.99 (-4.82%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 236.54 | undervalue

Operating Data

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 236.54
Beta -0.488
Diluted Shares Outstanding 17.14
Cost of Debt
Tax Rate -1.34
After-tax Cost of Debt 7.95%
Risk-Free Rate
Market Risk Premium
Cost of Equity 1.982
Total Debt 49.89
Total Equity 4,053.63
Total Capital 4,103.52
Debt Weighting 1.22
Equity Weighting 98.78
Wacc

Build Up Free Cash

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%13.27%2.37%0.32%-1.34%2.92%2.92%2.92%2.92%2.92%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.02-0.17-0.33-0.21-0.22-----
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 2.05
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -281.66
Equity Value -
Shares Outstanding 17.14
Equity Value Per Share -